We are live on !
Find out more
Lee Ainslie Maverick Capital
AUM
$11.3B
Turnover
71.56%
1-Year Est. Return
76.6%
Lee Ainslie is the founder of Maverick Capital, a long/short equity firm that emerged from the Tiger Management network of investors. Maverick is known for fundamental research, sector specialization among teams, and a classic hedge fund long/short structure. Ainslie’s firm remains a reference name among so-called Tiger Cub managers.
This Fund
S&P 500
This Quarter Est. Return
+47.05%
1 Year Est. Return
+76.6%
3 Year Est. Return
+266.43%
5 Year Est. Return
+219.63%
10 Year Est. Return
+601.38%
AUM
$11.3B
AUM Growth
+$2.65B
(+31%)
Cap. Flow
+$521M
Cap. Flow % of AUM
Cap. Flow %
4.6%
Top 10 Holdings %
Top 10 Hldgs %
42.81%
Holding
327
New
86
Increased
49
Reduced
40
Closed
148
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
1.1
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$467M |
| 2 |
Insmed
INSM
|
+$260M |
| 3 |
DPC
DPC Holdings PLC
DPC
|
+$250M |
| 4 |
GFL Environmental
GFL
|
+$240M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$204M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$410M |
| 2 |
Applied Materials
AMAT
|
+$400M |
| 3 |
Argan
AGX
|
+$253M |
| 4 |
TSMC
TSM
|
+$213M |
| 5 |
Linde
LIN
|
+$211M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.07% |
| 2 | Healthcare | 17.67% |
| 3 | Financials | 10.05% |
| 4 | Industrials | 9.89% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
51
Perrigo
PRGO
$2.25B
| $4.66M | 0.04% |
+448,053
| New | +$4.93M |
2026 Q2
0 quarters
|
|
52
The Magnum Ice Cream Company N.V.
MICC
$11.9B
| $4.58M | 0.04% |
+263,278
| New | +$4.1M |
2026 Q2
0 quarters
|
|
53
Novartis
NVS
$303B
| $4.36M | 0.04% |
27,789
+12,542
| +82% | +$1.88M |
2025 Q3
3 quarters
|
|
54
Bunge Global
BG
$19.2B
| $4.27M | 0.04% |
40,018
+16,043
| +67% | +$1.97M |
2026 Q1
1 quarter
|
|
55
Primo Brands
PRMB
$8.61B
| $4.09M | 0.04% |
167,188
-57,337
| -26% | -$1.27M |
2025 Q1
5 quarters
|
|
56
Scotiabank
BNS
$113B
| $3.99M | 0.04% |
46,020
+9,319
| +25% | +$734K |
2026 Q1
1 quarter
|
|
57
Seaboard Corp
SEB
$3.55B
| $3.85M | 0.03% |
863
+122
| +16% | +$639K |
2025 Q4
2 quarters
|
|
58
J&J Snack Foods
JJSF
$1.64B
| $3.72M | 0.03% |
+50,600
| New | +$3.94M |
2026 Q2
0 quarters
|
|
59
Turning Point Brands
TPB
$1.11B
| $3.69M | 0.03% |
43,489
+4,657
| +12% | +$387K |
2025 Q3
3 quarters
|
|
60
Altria Group
MO
$130B
| $3.61M | 0.03% |
50,201
-2,121
| -4% | -$148K |
2025 Q3
3 quarters
|
|
61
Vita Coco
COCO
$3.69B
| $3.42M | 0.03% |
51,659
-25,274
| -33% | -$1.71M |
2025 Q3
3 quarters
|
|
62
DELISTED
Kenvue
KVUE
| $3.32M | 0.03% |
173,991
+81,982
| +89% | +$1.44M |
2026 Q1
1 quarter
|
|
63
Fractyl Health
GUTS
$10.8M
| $3.16M | 0.03% |
331,234
| – | – |
2024 Q1
9 quarters
|
|
64
J.M. Smucker
SJM
$14.1B
| $3.12M | 0.03% |
27,733
-2,118
| -7% | -$216K |
2025 Q3
3 quarters
|
|
65
Brown-Forman Class B
BF.B
$13.8B
| $3.05M | 0.03% |
+114,286
| New | +$3.08M |
2026 Q2
0 quarters
|
|
66
Edgewell Personal Care
EPC
$1.32B
| $2.9M | 0.03% |
108,147
-57,095
| -35% | -$1.22M |
2026 Q1
1 quarter
|
|
67
Spectrum Brands
SPB
$2.03B
| $2.81M | 0.02% |
32,795
-35,031
| -52% | -$2.83M |
2025 Q4
2 quarters
|
|
68
Canadian National Railway
CNI
$76.6B
| $2.8M | 0.02% |
23,484
+4,709
| +25% | +$536K |
2026 Q1
1 quarter
|
|
69
Elanco Animal Health
ELAN
$13.2B
| $2.41M | 0.02% |
98,098
-46,359
| -32% | -$1.07M |
2025 Q3
3 quarters
|
|
70
Prestige Consumer Healthcare
PBH
$2.15B
| $2.41M | 0.02% |
+50,975
| New | +$2.62M |
2026 Q2
0 quarters
|
|
71
British American Tobacco
BTI
$131B
| $2.27M | 0.02% |
36,682
+1,629
| +5% | +$98.3K |
2025 Q3
3 quarters
|
|
72
Alcon
ALC
$34.5B
| $2.22M | 0.02% |
33,036
+20,304
| +159% | +$1.42M |
2026 Q1
1 quarter
|
|
73
Sanofi
SNY
$116B
| $2.2M | 0.02% |
51,572
+26,991
| +110% | +$1.21M |
2026 Q1
1 quarter
|
|
74
Coty
COTY
$3.55B
| $2.17M | 0.02% |
1,005,317
-256,516
| -20% | -$553K |
2026 Q1
1 quarter
|
|
75
Broadcom
AVGO
$1.74T
| $2.17M | 0.02% |
+5,734
| New | +$2.3M |
2026 Q2
0 quarters
|
|
Similar funds
GJL
Lee Ainslie's Q2 2026 Portfolio in Review
As of Q2 2026, Lee Ainslie held 327 positions worth $11.3B, up 31% from $8.67B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Lee Ainslie deployed $521M of net new capital in Q2 2026, opening 86 new positions and adding to 49 existing holdings. Its largest new stake was Meta Platforms (Facebook): 764,041 shares worth $430M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was ASML, an estimated $410M trimmed.
- Lee Ainslie's largest Q2 2026 buy was Meta Platforms (Facebook): 764,041 shares worth $430M.
- Lee Ainslie added most to GFL Environmental in Q2 2026, an estimated $240M increase.
- Lee Ainslie's biggest Q2 2026 reduction was ASML, cutting an estimated $410M.
- Lee Ainslie fully exited Argan in Q2 2026, selling an estimated $253M.
- Lee Ainslie's ten largest holdings make up 43% of its $11.3B portfolio in Q2 2026.
- Lee Ainslie opened 86 new positions and closed 148 in Q2 2026.
- Lee Ainslie's portfolio value rose 31% quarter-over-quarter to $11.3B.
Based on Maverick Capital's 13F filing for Q2 2026, filed 14 Aug 2026.